Skip to Main Content

Author Details

Mar??a D Odero
University of Navarra
1994
95
31
PMIDPaper TitleJournal TitlePublished Year
36455198Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.Blood2023
37190162Set Protein Is Involved in FLT3 Membrane Trafficking.Cancers (Basel)2023
37437699Regulation and role of the PP2A-B56 holoenzyme family in cancer.Biochim Biophys Acta Rev Cancer2023
33355179Endogenous Retroelement Activation by Epigenetic Therapy Reverses the Warburg Effect and Elicits Mitochondrial-Mediated Cancer Cell Death.Cancer Discov2021
34133718Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development.Blood2021
31593801A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity.Cancer Lett2020
31858592Data mining analysis of the PP2A cell cycle axis in mesothelioma patients.J Cell Physiol2020
31913266A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia.Blood Cancer J2020
32110991The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias.Cells2020
31316003Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".Sci Transl Med2019
29983874Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib.Oncotarget2018
27991928Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.Oncogene2017
28391050The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.Biochim Biophys Acta Gene Regul Mech2017
27092295Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.Front Oncol2016
28903318MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia.Oncotarget2016
27705940Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.Oncotarget2016
25801305New insights on the transcriptional regulation of CD69 gene through a potent enhancer located in the conserved non-coding sequence 2.Mol Immunol2015
26310075Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia.J Biomed Nanotechnol2015
25624456GATA2 germline mutations impair GATA2 transcription, causing haploinsufficiency: functional analysis of the p.Arg396Gln mutation.J Immunol2015
25637054CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.Haematologica2015
24405639Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.J Hematol Oncol2014
25567395Importance of genetics in acute myeloid leukemia.An Sist Sanit Navar2014
24781014Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity.Leukemia2014
24436473Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.Clin Cancer Res2014
22689058Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.Oncogene2013
23812941Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells.Haematologica2013
23353057Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines.Cancer Lett2013
21605981The role of the GATA2 transcription factor in normal and malignant hematopoiesis.Crit Rev Oncol Hematol2012
23077663Integration of SNP and mRNA arrays with microRNA profiling reveals that MiR-370 is upregulated and targets NF1 in acute myeloid leukemia.PLoS One2012
22912701Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.PLoS One2012
22143672Epigenetic regulation of miRNA genes in acute leukemia.Leukemia2012
22133779Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia.Haematologica2012
21904383Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities.Leukemia2012
21252985In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels.Leukemia2011
22069467Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas.PLoS One2011
21569010EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells.Br J Haematol2011
21750091Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.Haematologica2011
21233840PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.Leukemia2011
19965692SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia.Blood2010
22276033Spectral karyotyping (SKY).Ecancermedicalscience2010
20842122EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.Br J Cancer2010
20930122Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.Proc Natl Acad Sci U S A2010
19963127A novel t(7;13)(p12;q33 approximately q34) in AML-M2.Cancer Genet Cytogenet2009
18322257In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.Haematologica2008
18722879A new dic(7;12)(p12.21;p12.2) chromosome aberration in a case of acute myeloid leukemia.Cancer Genet Cytogenet2008
17175383A novel t(2;3)(p11;q27) in a case of follicular lymphoma.Cancer Genet Cytogenet2007
17914559Multicolor interphase cytogenetics for the study of plasma cell dyscrasias.Oncol Rep2007
18037989Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.J Clin Invest2007
17581610JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers.Leukemia2007
17377590DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups.Leukemia2007
  • 1 - 50 of 95

Recommended Authors

Il??ana Antony-Debr??
INSERM, France Villejuif Universite Paris-Saclay
Career Start Year 2011
Number of shared co-authors 0
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 2
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Career Start Year 2010
Number of shared co-authors 0
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 0
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 1
Zejuan Li
Houston Methodist Hospital
Career Start Year 2005
Number of shared co-authors 2
Anna L Brown
Adelaide Medical School, University of Adelaide
Career Start Year 2003
Number of shared co-authors 2
Rhonda E Ries
Clinical Research Division, Fred Hutchinson Cancer Research Center
Career Start Year 2003
Number of shared co-authors 3
Alexander Kohlmann
Oncology R&D
Career Start Year 2002
Number of shared co-authors 0
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 0
Gudrun G??hring
Hannover Medical School
Career Start Year 2002
Number of shared co-authors 2
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 0
Shinichiro Takahashi
Tohoku Medical and Pharmaceutical University Hospital.
Career Start Year 1998
Number of shared co-authors 0
Lukas D Wartman
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 1
Charles G Mullighan
St Jude Children's Research Hospital
Career Start Year 1996
Number of shared co-authors 5
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 3
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 4
Doris Steinemann
Hannover Medical School
Career Start Year 1994
Number of shared co-authors 4
Timothy A Graubert
Massachusetts General Hospital
Career Start Year 1993
Number of shared co-authors 1
Jean Soulier
University of Paris
Career Start Year 1993
Number of shared co-authors 3
Seishi Ogawa
Kyoto University
Career Start Year 1993
Number of shared co-authors 1
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 2
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 4
Arndt Borkhardt
Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf
Career Start Year 1992
Number of shared co-authors 0
Scott A Armstrong
Boston Children's Hospital
Career Start Year 1990
Number of shared co-authors 2
Mary Shago
The Hospital for Sick Children, University of Toronto
Career Start Year 1990
Number of shared co-authors 0
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Career Start Year 1989
Number of shared co-authors 0
Krzysztof Mr??zek
The Ohio State Comprehensive Cancer Center
Career Start Year 1988
Number of shared co-authors 0
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 1983
Number of shared co-authors 2
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 5

Collaborators

Raffaella Pippa
University of Navarra, Center for Applied Medical Research (CIMA)
Co-authored papers 13
Reiner Siebert
Co-authored papers 7
Dale J Christensen
TFF Pharmaceuticals, Inc.
Co-authored papers 3
Goutham Narla
The University of Michigan Medical School ann arbor
Co-authored papers 3
Marta M Alonso
CIMA-Universidad de Navarra
Co-authored papers 3
Michael P Vitek
Duke University Medical Center
Co-authored papers 3
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 2
Rosalie C Sears
Oregon Health and Science University
Co-authored papers 2
Nameeta P Richard
Randall Children's Hospital at Legacy Emanuel
Co-authored papers 1
Jiahuai Han
Co-authored papers 1
Javier Ben??tez
Instituto de Salud Carlos III
Co-authored papers 1
Juan Fueyo
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 1
Deanne Tibbitts
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Pieter Mestdagh
Co-authored papers 1
Ryan J Mackenzie
Oregon Health & Science University, USA [2] Knight Cancer Institute
Co-authored papers 1
Rafael Vald??s-Mas
Weizmann Institute of Science
Co-authored papers 1
Ido Amit
Weizmann Institute of Science
Co-authored papers 1
Jo Vandesompele
Co-authored papers 1
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 1
Frederick F Lang
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 1
Shawn Mahmood
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Nuria Lopez-Bigas
Universitat Pompeu Fabra
Co-authored papers 1
Bill H Chang
Oregon Health and Science University
Co-authored papers 1
Leander Van Neste
Maastricht University Medical Center
Co-authored papers 1
Alvaro Alonso
Rollins School of Public Health, Emory University
Co-authored papers 1
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 1
Julio Saez-Rodriguez
Institute of Computational Biomedicine, Heidelberg University
Co-authored papers 1
Candelaria Gomez-Manzano
The University of Texas M.D. Anderson Cancer Center
Co-authored papers 1
Xose S Puente
University of Oviedo
Co-authored papers 1
Release 1.2